Table 1
From the following article
Antivirals—an increasingly healthy investment
Brian McCarthy
Nature Biotechnology 25, 1390 - 1393 (2007)
doi:10.1038/nbt1207-1390
Table 1. HIV therapeutics with recent or imminent patent expirations
| Company | Drug (generic name) | Patent | Date of expiration |
|---|---|---|---|
| Nucleoside analog reverse transcriptase inhibitor | |||
| Bristol-Myers Squibb | Videx (dideoxyinosine) | US 5,254,539 | March 2007 |
| Bristol-Myers Squibb | Zerit (stavudine; d4T) | Various | June 2008 |
| Glaxo Wellcome | Ziagen (abacavir) | Various | June–December 2009 |
| Glaxo Wellcome | Combivir (lamivudine/zidovudine) | US 5,859,021 | May 2012 |
| Gilead | Emtriva (emtricitabine) | US 5,210,085 | July 2008 |
| Hoffmann-La Roche | Zalcitabine (ddC) | Various | July 2008 |
| Protease inhibitor | |||
| Hoffmann-La Roche | Invirase/Fortovase (saquinavir mesylate) | US 5,196,438 | November 2010 |